Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis：a prelimi-nary study

Chao YAN,Hongpeng SHI,Ying LIU,Wei XU,Tao MA,Wenqi XI,Zhongyin YANG,Zichen HUA,Wentao LIU,ZhengLun ZHU,Renda BI,Yanan ZHENG,Renhua FENG,XueXin YAO,MingMin CHEN,Chen LI,Jun ZHANG,Min YAN,Zhenggang ZHU

DOI: https://doi.org/10.16139/j.1007-9610.2017.01.008

2017-01-01

Abstract:Objective To investigate the efficiency and safety of neoadjuvant intraperitoneal and systemic chemothera-py (NIPS) in gastric cancer patients with peritoneal metastasis. Methods From April to October 2015, a total of 11 gastric cancer patients with peritoneal metastasis including 1 case with P1, 2 cases with P2 and 8 cases with P3 received one course of chemotherapy with 21 days. Intraperitoneal paclitaxel (PTX) was administered at 20 mg/m 2 via implanted subcu-taneous peritoneal access ports as well as intravenous PTX at 50 mg/m2 on day 1 and 8. S-1 was administered at 80 mg/(m2·d) for 14 consecutive days, followed by 7 days rest. Conversion gastrectomy was performed after NIPS in the patients who showed macroscopic disappear or apparent shrinkage of their peritoneal metastatic lesions at the second staging la-paroscopy. Results In all 11 patients, conversion gastrectomy was done in 8 patients (72.7%) with R0 gastrectomy in 5 cases (62.5%). The median number of course of NIPS chemotherapy before surgery was 6 (3-8) courses. The 1-year overall survival (OS) rate was 63.6%(7/11) in all patients. The 1-year OS rate of the patients with conversion gastrectomy and the patients with stage P3 reached to 87.5% (7/8) and 50.0% (4/8), respectively. The predominant toxicity was myelosuppres-sion with grade 3/4 both leukopenia and neutropenia in 18.2% (2/11) and 36.4% (4/11), respectively. NIPS-related and surgery-related mortality were not observed. Conclusions NIPS induction therapy was effective and safe for gastric cancer patients with peritoneal metastasis and deserved further study.